These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 33196710)
21. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748 [TBL] [Abstract][Full Text] [Related]
22. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors. Rathod LS; Dabhade PS; Mokale SN Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967 [TBL] [Abstract][Full Text] [Related]
23. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma. Wang Q; Tang Z; Li C; Li X; Su C Front Immunol; 2023; 14():1297588. PubMed ID: 37954616 [TBL] [Abstract][Full Text] [Related]
33. Potential Predictive Value of Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262 [No Abstract] [Full Text] [Related]
34. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499 [TBL] [Abstract][Full Text] [Related]
35. Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC. Fields AP; Ali SA; Justilien V; Murray NR Small GTPases; 2017 Jan; 8(1):58-64. PubMed ID: 27245608 [TBL] [Abstract][Full Text] [Related]
37. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma. Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834 [TBL] [Abstract][Full Text] [Related]
38. Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903 [No Abstract] [Full Text] [Related]
39. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049 [TBL] [Abstract][Full Text] [Related]
40. Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report. Li XX Am J Ther; 2021 Jul; 29(2):e269-e271. PubMed ID: 33416243 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]